Lixte Fundamentals

LIXT -  USA Stock  

USD 2.75  0.07  2.48%

Lixte Biotech Hlds fundamentals help investors to digest information that contributes to Lixte Biotech's financial success or failures. It also enables traders to predict the movement of Lixte Stock. This fundamental analysis module provides a way for investors to measures Lixte Biotech's intrinsic value by examining all of its available economic and financial indicators and drivers, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lixte Biotech stock. Please note, this module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Search Fundamentals 

 
Refresh

Lixte Cash and Equivalents Analysis

Lixte Biotech's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Cash 
 = 
Bank Deposits 
+  
Liquidities 
More About Cash and Equivalents | All Equity Analysis

Current Lixte Biotech Cash and Equivalents

    
  7.74 M  
Most of Lixte Biotech's fundamental indicators, such as Cash and Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lixte Biotech Hlds is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Compare to competition

In accordance with the recently published financial statements, Lixte Biotech Hlds has 7.74 M in Cash and Equivalents. This is 99.06% lower than that of the Healthcare sector and 98.27% lower than that of the Biotechnology industry. The cash and equivalents for all United States stocks is 99.71% higher than that of the company.

Lixte Biotech Hlds Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Lixte Biotech's current stock value. Our valuation model uses many indicators to compare Lixte Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lixte Biotech competition to find correlations between indicators driving Lixte Biotech's intrinsic value. More Info.
Lixte Biotech Hlds is rated below average in number of shares shorted category among related companies. It is rated below average in earnings per share category among related companies .

Lixte Earnings Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lixte Biotech's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lixte Biotech could also be used in its relative valuation, which is a method of valuing Lixte Biotech by comparing valuation metrics of similar companies.
Lixte Biotech is currently under evaluation in earnings per share category among related companies.

Lixte Fundamentals

About Lixte Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotech Hlds's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotech Hlds based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was incorporated in 2005 and is based in East Setauket, New York. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Lixte Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run CEO Directory Now

   

CEO Directory

Screen CEOs from public companies around the world
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Lixte Biotech Hlds using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Lixte Biotech Piotroski F Score and Lixte Biotech Altman Z Score analysis. Note that the Lixte Biotech Hlds information on this page should be used as a complementary analysis to other Lixte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Lixte Stock analysis

When running Lixte Biotech Hlds price analysis, check to measure Lixte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotech is operating at the current time. Most of Lixte Biotech's value examination focuses on studying past and present price action to predict the probability of Lixte Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lixte Biotech's price. Additionally, you may evaluate how the addition of Lixte Biotech to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
The market value of Lixte Biotech Hlds is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotech's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotech's market value can be influenced by many factors that don't directly affect Lixte Biotech Hlds underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Lixte Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.